Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
ALDX Stock Chart & Stats
$1.68
-$0.07(-1.37%)
At close: 4:00 PM EST
$1.68
-$0.07(-1.37%)
Day’s Range― - ―
52-Week Range$1.07 - $6.18
Previous CloseN/A
Volume102.94K
Average Volume (3M)4.81M
Market Cap
$101.11M
Enterprise Value$46.60M
Total Cash (Recent Filing)$70.04M
Total Debt (Recent Filing)$15.53M
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Apr 30, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding60,182,780
10 Day Avg. Volume11,754,580
30 Day Avg. Volume4,812,118
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-365.75
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.50Price Target Upside227.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$51.15M
Bulls Say, Bears Say
Bulls Say
Combined Clinical EfficacyCombined positive trial results indicate symptomatic and objective benefits for Reproxalap in dry eye, which may strengthen the regulatory case and improve market perception.
Commercial Partnership OpportunityAn outstanding option agreement with AbbVie offers a clear path for US development and commercialization, increasing the likelihood of a strategic partnership or acquisition.
Controlled Chamber StudyA highly controlled chamber study showed meaningful reduction in ocular discomfort, helping address variability in dry eye trials and reinforcing evidence of clinical activity.
Bears Say
Data Inconsistency And Methodological ConcernsRegulators highlighted inconsistent study results and baseline score imbalances across treatment groups, which undermine the reliability of the clinical program.
Market Competition RiskA crowded dry eye market with numerous prescription and over-the-counter options could limit Reproxalap's market penetration and revenue potential.
Regulatory Insufficiency (CRL)The FDA issued a Complete Response Letter citing a lack of substantial evidence from adequate and well-controlled studies, creating a major obstacle to approval.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.07 and its highest was $6.17 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $101.11M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 28 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Currently, no data Available
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,182,780 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (227.38% Upside)
$5.50 (227.38% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $105.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.31%
12-Months-Change
Fundamentals
Return on Equity
-63.75%
Trailing 12-Months
Asset Growth
-31.11%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Stock 12 Month Forecast
Average Price Target
$5.50
▲(227.38% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
10.48% Insiders
8.83% Mutual Funds
29.95% Other Institutional Investors
41.94% Public Companies and
Individual Investors